- Case Report
- Open access
- Published:
Ruthenibacterium lactatiformans isolated from a human blood culture: a first report
BMC Infectious Diseases volume 24, Article number: 699 (2024)
Abstract
Background
Ruthenibacterium lactatiformans, a Gram-stain-negative, rod-shaped, obligate anaerobic bacterium of the Oscillospiraceae family, has not been previously reported in human infections. This study reports the first case of bacteraemia and potential vertebral osteomyelitis caused by Ruthenibacterium lactatiformans.
Case presentation
An 82-year-old man with a history of diabetes, chronic renal failure, and prior spinal surgery for spondylolisthesis and spinal stenosis presented with fever and lower back pain. Magnetic resonance imaging revealed multiple vertebral osteomyelitis lesions. Initial blood cultures identified methicillin-resistant Staphylococcus aureus (MRSA), which prompted vancomycin treatment. However, repeated blood cultures not only confirmed persistent MRSA, but also detected Gram-negative bacilli (GNB). Despite surgical removal of the spinal hardware and antimicrobial therapy, the patient’s osteomyelitis worsened, necessitating transfer for further management. Subsequent analysis using 16S rRNA gene sequencing identified the GNB as Ruthenibacterium lactatiformans.
Conclusions
This is the first documented instance of human infection with Ruthenibacterium lactatiformans, signifying its pathogenic potential in vertebral osteomyelitis. The involvement of anaerobic bacteria and the possibility of polymicrobial infections complicate the diagnosis and treatment of vertebral osteomyelitis. This report underscores the need for caution when identifying the causative organism and selecting an appropriate treatment.
Introduction
Ruthenibacterium is a Gram-stain-negative, rod-shaped, obligate anaerobic bacterium that belongs to the family Oscillospiraceae [1]. There have been no reported cases of human infections caused by these bacteria, and their clinical significance and characteristics remain unknown. Here, we report a case of bacteraemia caused by Ruthenibacterium lactatiformans in a patient with vertebral osteomyelitis, highlighting its clinical course and treatment response.
Case presentation
An 82-year-old man with a history of diabetes mellitus and chronic renal failure was admitted to Osaka University Hospital with fever and lower back pain that started four days before admission. One year prior, he had undergone spinal surgery for posterior lumbar interbody fusion at L5/S1 for spondylolisthesis and posterior decompression from L2 to L4 for lumbar spinal stenosis. Postoperatively, the patient developed vertebral osteomyelitis caused by methicillin-resistant Staphylococcus aureus (MRSA). This complication necessitated removal of the L5/S1 cage, autologous bone grafting, and posterior fixation from the L3-L4-sacral-alar-iliac.
Upon admission, magnetic resonance imaging (MRI) revealed fluid accumulation at the L2/3 and L5/S1 levels, with high signal intensity in the adjacent soft tissues (Fig. 1). Initial blood cultures identified MRSA on day 2 of admission, leading to vancomycin treatment. The time-to-positive (TTP) was 17 h.
Blood cultures were incubated for 7Â days, and no additional bacteria were identified.
MRSA was detected in both aerobic and anaerobic bottles, and anaerobic culture was also performed, but no other bacteria were found. The patient was diagnosed as having vertebral osteomyelitis.
Blood samples revealed blood glucose level of 214Â mg/dL and HbA1c of 6.2%.
On day 7 of admission, the patient underwent surgery to remove the spinal hardware. MRSA was also isolated from surgical specimens. Then, on day 10 of admission, MRSA continued to be detected in repeated blood cultures, with small Gram-negative bacilli (GNB) were identified in the two sets of blood cultures. The TTP of these cultures was 63 h. The colonies of GNB showed minimal growth (Fig. 2) and could not be identified by matrix-assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI-TOF MS) using the MALDI Biotyper library (version 9) (Bruker Daltonics, https://www.bruker.com). We used ABHK media (Shimadzu Diagnostics) for the isolation of this microorganism. The isolation was performed under anaerobic conditions. To achieve anaerobiosis, we utilized the DIA anaero pack for pouches and DIA pouch bags (PHC). The cultures were incubated at 35 °C. Antimicrobial susceptibility testing for GNB was also unable because of the minimal growth. Under the combined treatment with vancomycin and ceftriaxone, the blood cultures turned negative on day 20 of admission. Since the bacteraemia improved, we determined to continue the ongoing therapy.
Ceftriaxone was administered for 16 days for GNB bacteraemia and vancomycin for eight weeks for the MRSA infection. Despite the completion of antibiotic treatment, the patient’s vertebral osteomyelitis worsened. Considering the possibility that GNB was the causative organism of vertebral osteomyelitis, ceftriaxone was resumed. On post-admission day 72, the patient was transferred for additional surgery. During the revision surgery, cultures from the vertebral body yielded only MRSA and no GNB were detected. Subsequent 16S rRNA gene sequence analysis identified the isolated GNB as Ruthenibacterium lactatiformans (GenBank accession number: JXXKH010000069) with 100% identity (1449/1449).
Discussion
Ruthenibacterium lactatiformans was first identified in 2016 in the faeces of a healthy individual [1]. Despite several studies exploring its presence in the gut microbiota and faeces [2,3,4], no further infections have been reported to date. Ruthenibacterium belongs to the Oscillospiraceae family but exhibits Gram-negative staining. Disc-diffusion experiments have suggested that this organism is resistant to amikacin, ampicillin, azithromycin, cephalothin, clindamycin, levofloxacin, linezolid, and penicillin G, but sensitive to amoxicillin-clavulanate and vancomycin [1].
The causative organisms of vertebral osteomyelitis are reported to be anaerobic bacteria in less than 3% of cases [5, 6] and polymicrobial infections in 7.8% of cases [7]. Although infections involving polymicrobial bacteria are rare in vertebral osteomyelitis, they do occur. In particular, anaerobic bacteria are generally difficult to detect, which increases their risk of being overlooked.
In the case reported herein, vertebral osteomyelitis may have been caused by a coinfection involving Ruthenibacterium lactatiformans and MRSA. Therefore, great care must be taken during the pathogenesis and treatment of vertebral osteomyelitis.
Malignancy is a known risk factor for anaerobic bacteraemia [8, 9], and based on previous reports of Ruthenibacterium lactatiformans detected in human stool, the search for colorectal cancer as an entry point for this bacterium was considered. However, a colonoscopy could not be performed upon admission to our hospital because of the patient’s severe back pain.
Conclusion
This case represents the first documented instance of rare bacteraemia and potentially vertebral osteomyelitis caused by Ruthenibacterium lactatiformans, providing significant insights into its pathogenic potential in human infections.
Availability of data and materials
The raw data of this article will be made available by the authors.
Abbreviations
- MRSA:
-
Methicillin-resistant Staphylococcus aureus
- MRI:
-
Magnetic resonance imaging
- GNB:
-
Gram-negative bacilli
- TTP:
-
Time-to-positive
- MALDI-TOF MS:
-
Matrix-assisted laser desorption ionisation time-of-flight mass spectrometry
References
Shkoporov AN, Chaplin AV, Shcherbakova VA, Suzina NE, Kafarskaia LI, Bozhenko VK, Efimov BA. Ruthenibacterium lactatiformans gen. nov., sp. nov., an anaerobic, lactate-producing member of the family Ruminococcaceae isolated from human faeces. Int J Syst Evol Microbiol. 2016;66:3041–9.
Consortium. i. Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course. Cell. 2022;185(3467–3486):e3416.
Cox LM, Maghzi AH, Liu S, Tankou SK, Dhang FH, Willocq V, Song A, Wasen C, Tauhid S, Chu R, et al. Gut microbiome in progressive multiple sclerosis. Ann Neurol. 2021;89:1195–211.
Lee JY, Mannaa M, Kim Y, Kim J, Kim GT, Seo YS. Comparative analysis of fecal microbiota composition between rheumatoid arthritis and osteoarthritis patients. Genes (Basel). 2019;10:748.
Saeed MU, Mariani P, Martin C, Smego RA Jr, Potti A, Tight R, Thiege D. Anaerobic spondylodiscitis: case series and systematic review. South Med J. 2005;98:144–8.
Chen CT, Wu MH, Huang TY, Li YY, Huang TJ, Lee CY, Lin CH, Lee CY. Anaerobic spondylodiscitis: a retrospective analysis. BMC Musculoskelet Disord. 2022;23:788.
McHenry MC, Easley KA, Locker GA. Vertebral osteomyelitis: long-term outcome for 253 patients from 7 Cleveland-area hospitals. Clin Infect Dis. 2002;34:1342–50.
Justesen US, Nielsen SL, Jensen TG, Dessau RB, Moller JK, Coia JE, Andersen SL, Pedersen C, Gradel KO. Bacteremia with anaerobic bacteria and association with colorectal cancer: a population-based cohort study. Clin Infect Dis. 2022;75:1747–53.
Zahar JR, Farhat H, Chachaty E, Meshaka P, Antoun S, Nitenberg G. Incidence and clinical significance of anaerobic bacteraemia in cancer patients: a 6-year retrospective study. Clin Microbiol Infect. 2005;11:724–9.
Acknowledgements
We gratefully acknowledge the bacteriological laboratory and clinical staff at Osaka University Hospital. We would like to thank Editage (www.editage.com) for English language editing.
Funding
Not applicable.
Author information
Authors and Affiliations
Contributions
SS conducted data collection, and prepared the original draft of the manuscript. KK conducted the data analysis and interpretation. SH co-authored the paper and contributed to the review and editing of the manuscript. KN (Katsuyuki Negishi), KN (Koshi Ninomiya), and MS were part of the attending physicians’ team and were responsible for the critical revision of the manuscript for important intellectual content. SK provided supervision and was involved in the review and editing of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
There was no involvement of the ethics committee.
Consent for publication
Written informed consent was obtained from the patient for the publication of this case report.
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Sumiyoshi, S., Hamaguchi, S., Kimura, K. et al. Ruthenibacterium lactatiformans isolated from a human blood culture: a first report. BMC Infect Dis 24, 699 (2024). https://doi.org/10.1186/s12879-024-09606-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s12879-024-09606-4